- Home
- GOSS vs ASA Comparison
GOSS vs ASA Comparison
Compare GOSS & ASA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- ASA
- Stock Information
- Founded
- GOSS 2015
- ASA 1958
- Country
- GOSS United States
- ASA United States
- Employees
- GOSS N/A
- ASA N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- ASA Precious Metals
- Sector
- GOSS Health Care
- ASA Industrials
- Exchange
- GOSS Nasdaq
- ASA Nasdaq
- Market Cap
- GOSS 586.6M
- ASA 697.1M
- IPO Year
- GOSS 2019
- ASA N/A
- Fundamental
- Price
- GOSS $2.94
- ASA $39.54
- Analyst Decision
- GOSS Strong Buy
- ASA
- Analyst Count
- GOSS 4
- ASA 0
- Target Price
- GOSS $8.50
- ASA N/A
- AVG Volume (30 Days)
- GOSS 3.3M
- ASA 158.9K
- Earning Date
- GOSS 11-06-2025
- ASA 09-19-2025
- Dividend Yield
- GOSS N/A
- ASA 0.15%
- EPS Growth
- GOSS N/A
- ASA 331.75
- EPS
- GOSS N/A
- ASA 14.01
- Revenue
- GOSS $40,237,000.00
- ASA $3,923,667.00
- Revenue This Year
- GOSS N/A
- ASA N/A
- Revenue Next Year
- GOSS $30.65
- ASA N/A
- P/E Ratio
- GOSS N/A
- ASA $2.82
- Revenue Growth
- GOSS N/A
- ASA 66.52
- 52 Week Low
- GOSS $0.66
- ASA $18.62
- 52 Week High
- GOSS $2.98
- ASA $40.19
- Technical
- Relative Strength Index (RSI)
- GOSS 76.74
- ASA 73.83
- Support Level
- GOSS $2.41
- ASA $38.10
- Resistance Level
- GOSS $2.71
- ASA $39.20
- Average True Range (ATR)
- GOSS 0.19
- ASA 0.90
- MACD
- GOSS 0.04
- ASA 0.31
- Stochastic Oscillator
- GOSS 96.37
- ASA 89.62
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About ASA ASA Gold and Precious Metals Limited
ASA Gold And Precious Metals Ltd is a closed-end, non-diversified investment company. Its objective is to provide long-term capital appreciation through investing in companies engaged in the exploration for, development of projects, or mining of precious metals and minerals.